Saturday 17 October 2026
Export HKPD’s income statement to Excel — free account
Cellyan Biotechnology Co., Ltd
HKPD Healthcare Medical Distribution
Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.
0.11
0.00
0.00%
Follow HKPD
| Mar '26 | Mar '25 | Mar '24 | Dec '23 | Mar '23 | Dec '22 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | — | — | — | — |
Altman Z-Score |
3.39 | 4.66 | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
7.32 | 5.84 | 6.34 | — | 2.85 | 2.85 |
Beneish M-Score |
(0.76) | (2.40) | (0.49) | — | — | — |
P/Operating CF |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
EV/Operating CF |
2.21 | (0.42) | 0.00 | — | 0.00 | 0.00 |
EV/FCF |
5.00 | (0.47) | 0.00 | — | 0.00 | 0.00 |
Quick Ratio |
3.75 | 2.80 | 1.77 | 0.00 | 1.00 | 1.00 |
Current Ratio |
3.86 | 2.99 | 2.46 | 0.00 | 1.08 | 1.08 |
Net Debt/EBITDA |
(0.79) | (5.45) | 0.49 | 0.00 | (0.19) | (0.40) |
Debt/Assets |
7.34% | 19.98% | 16.76% | 0.00% | 9.13% | 3.07% |
Debt/Equity |
0.10 | 0.38 | 0.34 | — | 0.53 | 0.18 |
Asset Turnover |
1.21 | 2.25 | 2.45 | 0.00 | 3.69 | 0.00 |
Operating CF/Net income |
0.66 | (21.00) | (0.30) | 0.00 | 1.73 | 0.00 |
Capex/Depreciation |
(0.49) | (2.04) | (0.85) | — | (1.59) | — |
Interest Coverage |
(7.48) | 1.34 | 19.42 | — | 44.99 | 44.99 |
| (15.59%) | (0.59%) | 54.96% | 0.00% | 253.80% | 0.00% | |
| (10.21%) | (0.30%) | 19.49% | 31.71% | 29.30% | 0.00% | |
ROIC |
(6.07%) | 2.11% | 19.79% | 0.00% | 175.61% | 395.14% |
Return on Tangible Assets |
(12.35%) | (0.46%) | 28.12% | 26.69% | 285.77% | 285.77% |
Average Days of Receivables |
319.30 | 92.74 | 108.94 | 0.00 | 59.10 | 59.10 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
17.83% | 10.91% | 11.32% | 0.00% | 14.00% | 13.50% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% |
Revenue per Share |
0.82 | 1.99 | 2.27 | — | 1.83 | 0.00 |
Operating CF per Share |
(0.05) | 0.06 | (0.05) | — | 0.25 | — |
Capex per Share |
0.00 | (0.02) | (0.01) | — | (0.02) | — |
Free Cash Flow per Share |
(0.05) | 0.04 | (0.06) | — | 0.24 | — |
Cash per Share |
0.01 | 0.29 | 0.09 | — | 0.08 | 0.00 |
Shareholders Equity per Share |
0.59 | 0.49 | 0.58 | — | 0.09 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Book value per Share |
0.59 | 0.49 | 0.58 | — | 0.09 | 0.00 |
Free Cash Flow |
(0.79) | 0.41 | (0.45) | — | 1.61 | — |
Working Capital |
9.14 | 5.81 | 4.63 | 4.98 | 0.20 | 0.20 |
Capital Expenditures |
(0.04) | (0.15) | (0.05) | — | (0.12) | — |
Net Current Asset Value |
9.07 | 4.30 | 3.39 | 4.98 | (0.07) | (0.07) |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.01 | 0.00 | — | 0.01 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
1.47 | 0.68 | 0.62 | — | 0.49 | 0.00 |
Cash ROIC |
(7.39%) | 4.19% | (7.09%) | — | 113.28% | 0.00% |
Accounts Receivable Turnover |
1.59 | 4.01 | 3.35 | 0.00 | 6.18 | 0.00 |
Accounts Payable Turnover |
8.94 | 11.06 | 8.86 | — | 0.00 | 0.00 |
Inventory Turnover |
26.19 | 23.97 | 23.36 | — | 51.43 | 0.00 |
Average Days of Payables |
26.48 | 37.15 | 39.37 | — | 57.60 | 0.00 |
Days of Inventory on Hand |
10.91 | 11.42 | 25.95 | — | 7.10 | 7.10 |
Average Receivables |
8.46 | 5.07 | 4.98 | 3.51 | 2.03 | — |
Average Payables |
1.35 | 1.62 | 1.48 | — | — | — |
Average Inventory |
0.46 | 0.75 | 0.56 | — | 0.19 | — |
Average Assets |
11.13 | 9.04 | 6.82 | 4.19 | 3.41 | — |
Average Common Equity |
7.29 | 4.62 | 2.42 | — | 0.39 | — |
Columns are period end dates